Literature DB >> 1670664

Measurement of anti-GOR antibodies in prevention of post-transfusion non-A, non-B hepatitis.

H Yoshizawa, N Nojiri, K Takahashi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1670664     DOI: 10.1016/0140-6736(91)93364-f

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment.

Authors:  J Hayashi; S Kashiwagi
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

2.  Managing chronic hepatitis C virus infection.

Authors:  J Y Lau; G L Davis
Journal:  BMJ       Date:  1993-02-20

3.  The GOR gene product cannot cross-react with hepatitis C virus in humans.

Authors:  R Koike; T Iizuka; T Watanabe; N Miyasaka
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

4.  Immune response to GOR, a marker for non-A, non-B hepatitis and its correlation with hepatitis C virus infection.

Authors:  S U Mehta; S Mishiro; K Sekiguchi; T Leung; G J Dawson; L M Pendy; D A Peterson; S G Devare
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

5.  Molecular basis for antibody cross-reactivity between the hepatitis C virus core protein and the host-derived GOR protein.

Authors:  Z X Zhang; M Chen; K Wallhagen; J Trojnar; L O Magnius; B Wahren; M Sällberg
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

6.  Serum immunoglobulin G antibodies to the GOR autoepitope are present in patients with occult hepatitis C virus (HCV) infection despite lack of HCV-specific antibodies.

Authors:  Juan A Quiroga; Inmaculada Castillo; Javier Bartolomé; Vicente Carreño
Journal:  Clin Vaccine Immunol       Date:  2007-08-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.